Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Synthetic Blood (SYBD) -- Ignore unavailable to you. Want to Upgrade?

To: Eric Beckman who wrote (183)	5/27/1998 1:16:00 PM
From: Lance	Respond to of 307

It may not be earth shattering but i think it is just part of the puzzle they are putting together here and we will see the fruits of all this sooner or later. Lance

To: Eric Beckman who wrote (183)	5/27/1998 9:42:00 PM
From: Rick Hoffmann	Read Replies (1) \| Respond to of 307

Did a quick check on his scientific background through the IBM patent database-found nothing of particular interest. The patents listed for "Howard Jones" showed no experience in fluorocarbon products, biosensors or even electrochemistry. The Edgar database had some info on a "Cypros Pharmaceutical Corp" whose stock has about the same value as Alliance Pharmaceutical, around 4 1/2 per share. They have accumulated losses of about $10MM over the 92-97 years. My feeling is that this is another release which looks good, but really contains nothing of substance except to make the company more topheavy. SBI certainly didn't compare well with the other companies in the article on blood substitutes in the May 18 issue of Chemical and Engineering News.